Article Details

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 ...

Retrieved on: 2022-12-27 22:26:52

Tags for this article:

Click the tags to see associated articles and topics

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 .... View article details on HISWAI: https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/gilead-to-acquire-all-remaining-rights-to-potential-first-in-class-immunotherapy-gs-1811-from-jounce-therapeutics

Excerpt

“GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with ...

Article found on: www.gilead.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up